Back to article: Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy

FIGURE 2: Effect of cytostatic drugs on tumor and immune cells and during anti-tumor immunity. (A) Effect of MEKi on tumor cell viability, expression of pro-inflammatory genes and MHC-I/-II protein levels in presence of low doses IFNγ. Effect of MEKi and GEM on T cell expansion in in vivo OT-I T cell proliferation assays. (B) Anti-tumor efficacy and PD biomarker gene signatures of combinations therapies involving cytostatic agents GEM and MEKi and immunostimulatory antibodies targeting CD40 and PD-1.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.